T-large granular lymphocyte
leukemia (T-LGLL) is a chronic clonal proliferation
of effector memory cytotoxic CD3+CD57+CD56- T
cells and the current guidelines suggest
immunosuppressive therapy as first-line therapy, but
the treatment of refractory/relapsed patients is still
challenging due to the lack of prospective studies.
We describe a series of two refractory/relapsed
T-LGLL patients successfully treated with
bendamustine, a chemotherapeutic agent largely used
for B-cell neoplasms, but poorly investigated for the
treatment of T-cell diseases. Complete remission
(CR) was achieved in 3 and 6 months, respectively,
and maintained for at least 20 months. One patient
relapsed after a 20-month CR, but she was
responsive to bendamustine therapy again, obtaining
a further prolonged CR.
Bendamustine as single agent or in combination
could be a feasible therapeutic option in
refractory/relapsed T-LGLL, especially for elderly
patients because of its safety profile